Sonia Gulati on Blogger

Thursday, October 22, 2020

Women in VC Use Slack to Facilitate Global Collaboration

A New York-based venture capitalist with a background in life sciences, Sonia Gulati works as an executive in residence at Kairos Ventures. With a Ph.D. in biochemistry from Columbia University, she worked as an assistant director at New York Ventures, a $100-million seed early stage-venture fund. Sonia Gulati is a member of Women in VC.

Women in VC is a directory that brings together women investors to help them find each other and connect in a community where they can exchange ideas and share experiences. With a global membership base, technology has stepped in to facilitate seamless communication within the digital community. Women in VC Slack Group is a private member platform that allows members to engage using Slack across close to 100 various channels.

With over 2,100 members, Slack’s channels act as powerful micro-communities that exist within a wider global community network. In these online forums, members share resources, plan educational webinars as well as arrange both virtual and in-person networking events. Slack members also share investment opportunities, industry events, job postings, emerging manager resources as well as sector and geography-specific trends. To date, over 70,000 messages have been shared on the Slack platform.

Wednesday, May 6, 2020

A Snapshot of the Kairos Ventures Portfolio

Biotechnology and business development veteran Sonia Gulati holds a PhD from Columbia University, where she received a number of honors, including the Marija Chouinard Award for Excellence in Research. Currently, Sonia Gulati serves as the executive- in-residence at Kairos Ventures in New York, where she works closely with scientists to execute commercialization plans for portfolio companies.

Since its founding in 2015, Kairos Ventures has nourished global scientific discoveries through an expert-driven investment and commercialization process. The firm focuses its efforts on startups and formative-stage companies. Currently, Kairos Ventures invests in over 80 entities that include:

*1200 Pharma - a pharmaceutical firm that accelerates preclinical discovery and clinical approval timelines by applying innovative medicinal chemistry technology.

*Behavioral Signals - a technology firm that develops human behavior analysis and emotion- tracking solutions.

*Xidas - a micro-device production firm that develops products for high-value business sectors like aerospace and medicine.

*nFugue - a developer of nano-architected materials for industries that include healthcare, textiles, and aerospace.

For a complete list of the companies in Kairos Ventures’ portfolio, visit www.kairosventures.com.

About Sonia Gulati

A member of Women in VC, Sonia Gulati is a New York-based venture capitalist with a background in metabolic biochemistry and is currently an Executive in Residence at Kairos Ventures. In this capacity, she works closely with founding scientists to develop and execute on a commercialization plan that will de-risk technologies as they are spun out of academia. Prior to joining the firm in 2019, Sonia Gulati spent two years as an assistant director at New York Ventures, where she sourced and led six early stage life science investments, totaling $8.2 million. Sonia Gulati also served as board observer for seven early stage life science companies.

Before shifting her career focus to venture capital, Sonia Gulati worked as a consultant at BluePrint Research Group, where worked with biopharma clients to help inform their product launch and life cycle management strategies.

Prior to joining BluePrint Research Group, Sonia Gulati conducted her postdoctoral and predoctoral research at Columbia University where she focused on malaria drug development and lipid metabolism. Dr. Sonia Gulati spent the first decade of her career as a freelance science writer and ghost wrote numerous articles for peer-reviewed journals. She also ghost wrote and edited grants for academic and non-profit institutions.